Rearming the body’s immune system to fight cancer

We’re developing more precise and more accessible treatment alternatives for patients with solid cancers

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Learn more about us

Some of our partners

Latest news

Innovative Cancer Solutions: Cartherics’ Patented Immunotherapy Approach

By Karen Loudon / June 14, 2024
In a recent interview with Wholesale Investor, Cartherics’ COO, Dr Ian Nisbet shares deep insights into the company’s groundbreaking work...
Read More

Cartherics secures Australian patent for innovative cancer cell therapy

By Karen Loudon / June 12, 2024
Melbourne, Australia, 12 June 2024 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for...
Read More

Cartherics granted European patent for multiple development candidates

By Karen Loudon / May 23, 2024
Melbourne, Australia, 23 May 2024 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for...
Read More
1 2 3 59